PSMD2
ENSG00000175166
Target class
Enzyme
Chromosome
3
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- PSMD2
- Gene name
- Proteasome 26S subunit ubiquitin receptor, non-ATPase 2
- Gene symbol
- PSMD2
- Protein name
- 26S proteasome non-ATPase regulatory subunit 2 (26S proteasome regulatory subunit RPN1) (26S proteasome regulatory subunit S2) (26S proteasome subunit p97) (Protein 55.11) (Tumor necrosis factor type 1 receptor-associated protein 2)
- S2
- P97
- TRAP2
- MGC14274
- Rpn1
- Gene biotype
- Protein coding
- Gene family
- Proteasome|Armadillo like helical domain containing
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 193.62
- Tissue specificity (Gini)
- 0.217
- Tissue specificity (tau)
- 0.566
- KEGG gene identifiers
- hsa:5708
- Protein interaction confidence
- 0.897064
- Protein interaction partners
- 94
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 43 more, listed on the interactive page.
- End position
- 184309054
- Start position
- 184299157
- Chromosome
- 3
- Strand
- Forward
- Centriolar satellite
- Cytokinetic bridge
- Cytosol
- Flagellar centriole
- Nucleoplasm
- Tissue specificity (tau)
- 0.566235
- Expression inequality (Gini)
- 0.21667
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 193.62
- Testis
- 184.45
- Muscle - Skeletal
- 183.34
- Uterus
- 123.46
- Cells - EBV-transformed lymphocytes
- 119.94
Expression in transcripts per million
- Cells - Cultured fibroblasts193.62
- Testis184.45
- Muscle - Skeletal183.34
- Uterus123.46
- Cells - EBV-transformed lymphocytes119.94
- Skin - Sun Exposed (Lower leg)111.9
- Brain - Cerebellum110.55
- Adrenal Gland109.25
- Esophagus - Muscularis108.73
- Colon - Sigmoid107.14
- Artery - Tibial105.97
- Esophagus - Gastroesophageal Junction105.61
- Nerve - Tibial104.48
- Brain - Cerebellar Hemisphere103.45
- Skin - Not Sun Exposed (Suprapubic)103.38
- Cervix - Ectocervix100.15
- Artery - Aorta99.22
- Cervix - Endocervix99.18
- Esophagus - Mucosa98.85
- Lung97.8
- Fallopian Tube97.15
- Thyroid95.56
- Artery - Coronary94.5
- Adipose - Subcutaneous93.8
- Pituitary93.6
And 29 more, listed on the interactive page.
- GO:0000502
- GO:0005576
- GO:0005654
- GO:0005829
- GO:0005838
- GO:0016020
- GO:0034774
- GO:0070062
- GO:1904813
Molecular functions
- GO:0005515
Related records
Trials (789)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (5)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor